C WorldWide Group’s Neurocrine Biosciences NBIX Stock Holding History

C WorldWide Group’s Portfolio NBIX Stock Details NBIX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$16.5M	Hold	125,000	–	–	0.35%	36
2025 Q4	$17.7M	Hold	125,000	–	–	0.31%	40
2025 Q3	$17.5M	Sell	125,000 -10,000	-7%	-$1.35M	0.27%	41
2025 Q2	$17M	Buy	135,000 +20,000	+17%	+$2.29M	0.23%	41
2025 Q1	$12.7M	Hold	115,000	–	–	0.16%	56
2024 Q4	$15.7M	Buy	115,000 +20,000	+21%	+$2.47M	0.19%	46
2024 Q3	$10.9M	Buy	95,000 +20,000	+27%	+$2.74M	0.11%	66
2024 Q2	$10.3M	Buy	+75,000	New	+$10.3M	0.11%	64

Other funds holding NBIX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

C WorldWide Group's NBIX Position: Q1 2026 in Review

C WorldWide Group held its Neurocrine Biosciences (NBIX) position steady in Q1 2026 at 125,000 shares worth $16.5M. The position accounts for 0.35% of the portfolio, ranked #36.

C WorldWide Group first reported a position in NBIX in Q2 2024 and has held it in 8 quarters since. The position peaked at $17.7M in Q4 2025. 695 funds tracked by Wall St. Rank hold NBIX as of Q1 2026.

C WorldWide Group held 125,000 shares of Neurocrine Biosciences worth $16.5M as of Q1 2026.
C WorldWide Group left its Neurocrine Biosciences share count unchanged in Q1 2026.
Neurocrine Biosciences made up 0.35% of C WorldWide Group's portfolio in Q1 2026, its #36 holding.
C WorldWide Group first reported a position in Neurocrine Biosciences in Q2 2024 and has held it in 8 quarters since.
C WorldWide Group's Neurocrine Biosciences position peaked at $17.7M in Q4 2025.
695 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q1 2026.

Based on C WorldWide Group's 13F filing for Q1 2026, filed 6 May 2026.